Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Other Working Capital Changes: 2022-2025

Historic Other Working Capital Changes for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Sep 2025 value amounting to $3.9 million.

  • Centessa Pharmaceuticals' Other Working Capital Changes rose 198.08% to $3.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.6 million, marking a year-over-year increase of 76.17%. This contributed to the annual value of -$10.2 million for FY2024, which is 442.70% down from last year.
  • As of Q3 2025, Centessa Pharmaceuticals' Other Working Capital Changes stood at $3.9 million, which was up 183.71% from -$4.7 million recorded in Q2 2025.
  • Centessa Pharmaceuticals' 5-year Other Working Capital Changes high stood at $7.9 million for Q4 2022, and its period low was -$5.1 million during Q4 2023.
  • In the last 3 years, Centessa Pharmaceuticals' Other Working Capital Changes had a median value of -$1.1 million in 2023 and averaged -$926,545.
  • In the last 5 years, Centessa Pharmaceuticals' Other Working Capital Changes skyrocketed by 258.98% in 2023 and then slumped by 414.66% in 2025.
  • Centessa Pharmaceuticals' Other Working Capital Changes (Quarterly) stood at $7.9 million in 2022, then crashed by 164.15% to -$5.1 million in 2023, then increased by 11.88% to -$4.5 million in 2024, then spiked by 198.08% to $3.9 million in 2025.
  • Its last three reported values are $3.9 million in Q3 2025, -$4.7 million for Q2 2025, and $2.7 million during Q1 2025.